Onconetix (ONCO) EBITDA Margin (2024 - 2026)
Onconetix (ONCO) posted quarterly EBITDA Margin of 1452.39% for Q4 2025, up 264127.0% year-over-year from N/an in Q4 2024, and down 113.13% quarter-over-quarter from 681.45% in Q3 2025.
Onconetix (ONCO) EBITDA Margin (2024 - 2026) Analysis & Trends
Onconetix (ONCO) has reported EBITDA Margin for 2 consecutive years, with 1452.39% the latest figure, recorded in Q4 2025.
- In Q4 2025, EBITDA Margin rose 264127.0% year-over-year to 1452.39%; the TTM figure through Mar 2026 stood at 3112.51% (down 8784.0% YoY), while the FY2025 annual figure was 2976.14%, down 73818.0% from the prior year.
- EBITDA Margin eased to 1452.39% in Q4 2025 per ONCO's latest filing, from 681.45% in the prior quarter.
- Across five years, EBITDA Margin topped out at 661.47% in Q3 2024 and bottomed at 12570.83% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.75% |
| 10 | Onconetix | 1.42 Mn | -4.52 Mn | 4,303.00 | -15,950.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15,950.88% |
| Mar 31, 2026 | -47,657.18% |
| Dec 31, 2025 | -1,452.39% |
| Sep 30, 2025 | -681.45% |
| Jun 30, 2025 | -1,817.40% |
| Mar 31, 2025 | -12,570.83% |
| Dec 31, 2024 | -4,093.66% |
| Sep 30, 2024 | -661.47% |
| Jun 30, 2024 | -1,931.62% |
| Mar 31, 2024 | -1,582.16% |